Tower Research Capital (TRC)’s Envoy Medical COCH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.77K Buy
5,665
+2,106
+59% +$1.44K ﹤0.01% 4270
2025
Q4
$2.35K Sell
3,559
-552
-13% -$437 ﹤0.01% 4548
2025
Q3
$3.19K Buy
4,111
+872
+27% +$1.18K ﹤0.01% 4535
2025
Q2
$4.6K Sell
3,239
-328
-9% -$480 ﹤0.01% 4292
2025
Q1
$4.64K Sell
3,567
-682
-16% -$1K ﹤0.01% 4224
2024
Q4
$6.08K Buy
4,249
+2,937
+224% +$6.67K ﹤0.01% 4210
2024
Q3
$4.26K Sell
1,312
-2,729
-68% -$7.42K ﹤0.01% 4620
2024
Q2
$9.54K Buy
+4,041
New +$15K ﹤0.01% 4234
2024
Q1
Sell
-1,714
Closed -$3.1K 5883
2023
Q4
$3.1K Buy
+1,714
New +$3.36K ﹤0.01% 5124
2023
Q2
Sell
-303
Closed -$3K 6070
2023
Q1
$3K Buy
+303
New +$3.04K ﹤0.01% 5177
2022
Q3
Sell
-131
Closed -$1K 6109
2022
Q2
$1K Buy
131
+130
+13,000% +$1.27K ﹤0.01% 5755
2022
Q1
$0 Sell
1
-693
-100% -$6.74K ﹤0.01% 6135
2021
Q4
$7K Buy
+694
New +$6.77K ﹤0.01% 4899

Other funds holding COCH

Tower Research Capital (TRC)'s COCH Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Envoy Medical (COCH) stake by 59% in Q1 2026, buying an estimated $1.44K and bringing the position to 5,665 shares worth $3.77K. The position accounts for ﹤0.01% of the portfolio, ranked #4270.

Tower Research Capital (TRC) first reported a position in COCH in Q4 2021 and has held it in 13 quarters since. The position peaked at $9.54K in Q2 2024. 33 funds tracked by Wall St. Rank hold COCH as of Q1 2026.

  • Tower Research Capital (TRC) held 5,665 shares of Envoy Medical worth $3.77K as of Q1 2026.
  • Tower Research Capital (TRC) bought 2,106 Envoy Medical shares in Q1 2026, an estimated $1.44K.
  • Envoy Medical made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #4270 holding.
  • Tower Research Capital (TRC) first reported a position in Envoy Medical in Q4 2021 and has held it in 13 quarters since.
  • Tower Research Capital (TRC)'s Envoy Medical position peaked at $9.54K in Q2 2024.
  • 33 funds tracked by Wall St. Rank held Envoy Medical as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.